Equillium, Inc. develops novel therapeutics for severe autoimmune and inflammatory disorders. News about EQ centers on EQ504, the company’s investigational aryl hydrocarbon receptor, or AhR, modulator, including preclinical data, clinical-development planning, and disease-area positioning in ulcerative colitis, other gastrointestinal diseases, and inflammatory lung diseases.
Company updates also cover financing activity, operating results, corporate presentations, and equity-award disclosures under Nasdaq inducement-grant rules. These items reflect Equillium’s focus on immunobiology, immunomodulatory assets, capital resources for research and development, and public-company compensation and governance practices.
Equillium (EQ) will present new EQ504 preclinical data at the La Jolla Immunology Conference on October 6, 2026.
In an intestinal co-culture model, which studies intestinal cells together, EQ504 preserved barrier integrity while suppressing inflammatory cytokine production, or immune signaling proteins. The company said these findings support EQ504’s potential to address barrier dysfunction and inflammation in ulcerative colitis. Poster I-37 is scheduled for 11:00am to 1:00pm PT.
Equillium (EQ) received Australian regulatory clearance to initiate its first-in-human Phase 1 clinical trial of EQ504 in healthy participants. The trial received Human Research Ethics Committee approval and Therapeutic Goods Administration clearance under Australia's Clinical Trial Notification scheme.
The randomized, double-blind, placebo-controlled study will evaluate safety, tolerability, how the body processes EQ504 and its biological effects to assess proof of mechanism. Equillium expects dosing to begin by early November 2026, with topline Phase 1 proof-of-mechanism data anticipated approximately six months after study initiation. Subject to supportive Phase 1 data, the company anticipates starting a placebo-controlled proof-of-concept study in patients with moderately to severely active ulcerative colitis in the second half of 2027.
Equillium (Nasdaq: EQ) will present new EQ504 preclinical findings in two posters at the 7th International AHR Conference in Porto, Portugal.
The conference runs September 29 to October 2, 2026. One poster describes effects on intestinal barrier integrity across laboratory, translational and animal models, including regulation of proteins that seal gaps between cells and inflammatory signals. The other describes suppression of pro-inflammatory immune pathways and enhancement of regulatory pathways that support immune tolerance and tissue repair. Equillium views these preclinical findings as supporting EQ504’s potential for ulcerative colitis and other immune-mediated disorders; they are not human clinical results.
Equillium (EQ) will participate in a fireside chat at Stifel’s 2026 Virtual Immunology and Inflammation Forum on Wednesday, September 23, 2026 at 12:00 p.m. EDT.
Equillium management will also be available for meetings with registered conference investors. A live webcast of the fireside chat will be accessible via the Events & Presentations page in the Investor Relations section of equilliumbio.com, with a replay available for approximately 45 days after the conference.
Equillium (EQ) will participate in two upcoming investor conferences in September 2026, featuring presentations and investor meetings.
The company will join the Cantor Global Healthcare Conference 2026 on September 9, 2026 at 9:45 AM EDT via a fireside chat and 1x1 meetings, and the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026 at 11:00 AM EDT with a company presentation and 1x1 meetings. A live webcast and 45-day replay of the Cantor fireside chat will be available through Equillium’s Investor Relations Events & Presentations page.
Equillium (Nasdaq: EQ) reported second quarter 2026 results and corporate updates focused on advancing lead asset EQ504, a selective aryl hydrocarbon receptor modulator. The company plans to submit its Phase 1 dossier in Australia imminently, with a proof‑of‑mechanism SAD/MAD study in healthy volunteers expected to start in Q4 2026 and topline data about six months later.
Equillium is also conducting IND‑enabling work to develop EQ504 as an inhaled therapy for inflammatory lung diseases and EQ302 for celiac disease, and has formed a Clinical Advisory Board for the ulcerative colitis program. Cash and cash equivalents were $57.2 million on June 30, 2026, up from $30.3 million at year‑end 2025, which Equillium believes can fund current plans into 2029. Q2 2026 R&D expenses were $2.8 million and G&A $2.4 million, leading to a net loss of $4.7 million, or $(0.04) per share, compared with a $5.7 million loss a year earlier.
Equillium (Nasdaq: EQ) granted an inducement award of nonstatutory stock options to a new employee under its 2024 Inducement Plan.
The award covers 145,000 shares at an exercise price of $3.08 per share, vesting over four years, and was approved under Nasdaq Listing Rule 5635(c)(4).
Equillium (Nasdaq: EQ) announced that its management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 4:55 p.m. EDT. Registered conference investors will also have the opportunity to meet with Equillium’s management team.
Equillium (Nasdaq: EQ) will host a virtual investor webinar on May 27, 2026 at 11:00 AM ET. Chief Scientific Officer Stephen Connelly, Ph.D. will present new preclinical data on Aryl Hydrocarbon Receptor (AhR) modulators and the miR-124 axis in immune and epithelial cells.
The event will share findings that propose a unifying mechanistic framework linking ligand-dependent AhR signaling to miR-124, with implications for inflammatory disease therapy development. A live Q&A and a replay will be available to investors.
Equillium (Nasdaq: EQ) reported first quarter 2026 results and key updates centered on lead candidate EQ504.
The company plans a Phase 1 proof-of-mechanism study for EQ504 in mid-2026 with data about six months later, completed a $35 million private placement, appointed Snehal Naik, Ph.D. as Chief Development Officer, reduced operating expenses and net loss versus 2025, and ended the quarter with $61.3 million in cash, which is expected to fund currently planned operations into 2029.